New Delhi: Vaccine maker Bharat Biotech on Saturday said the death of a volunteer in Bhopal, who took a shot of its COVID-19 vaccine Covaxin as part of the Phase III clinical trials, was not related to the medication.
“As per the post-mortem report issued by the Gandhi Medical College, Bhopal that the site received from the Bhopal Police, the probable cause of death was due to cardio respiratory failure as a result of suspected poisoning and the case is under police investigation as well,” the Hyderabad-based firm said in a statement.
The volunteer passed away nine days after the dosing and preliminary reviews by the site indicate that the death is unrelated to the study dosing, it noted.
“We cannot confirm if the volunteer received the study vaccine or a placebo as the study is blinded,” the vaccine major noted.
The Drugs Controller General of India (DCGI) has approved Oxford-AstraZeneca COVID-19 vaccine Covishield, manufactured by the Serum Institute and Bharat…
